Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane - Related Studies

Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane

This study is ongoing, but not recruiting participants.

Study NCT00036270. Last updated on November 22, 2008. Information provided by Pfizer

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Neoplasms

2	More general conditions related to this trial
		Breast Diseases
		Neoplasms
		Neoplasms by Site
		Skin Diseases

3	Interventions listed in this trial
		exemestane (Aromasin)
		tamoxifen + exemestane

4	Additional drug interventions recognized in this trial
		Exemestane
		Tamoxifen

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Antineoplastic Agents, Hormonal
		Aromatase Inhibitors
		Bone Density Conservation Agents
		Enzyme Inhibitors
		Estrogen Antagonists
		Estrogen Receptor Modulators
		Hormone Antagonists
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Selective Estrogen Receptor Modulators
		Therapeutic Uses

6	Sponsors listed in this trial
		Pfizer